Weight regain after stopping semaglutide: the data and the 5-year cost math
Two-thirds of weight lost returns within a year of stopping. The STEP 1 extension data, the decade-level cost of staying on treatment, and why the plan you pick matters.
STEP 1 extension: what happens when you stop
The STEP 1 extension followed 327 participants for a year after the 68-week trial ended. On treatment, mean loss was 17.3%. A year after stopping, participants had regained 11.6 percentage points — a net loss of just 5.6% from baseline. Blood pressure, lipids, and other cardiometabolic gains reverted toward baseline as well. The message is not that semaglutide fails; it's that its benefits are present while you take it and largely reverse when you stop.
The maintenance economics
Chronic treatment has chronic costs. The question isn't whether you spend $145/month for one year — it's whether you spend it for five or ten. Flat-rate at $145/month totals $8,700 over five years and $17,400 over ten. A membership model at ~$230 totals $13,800 and $27,600. Brand retail totals roughly $81,000 and $162,000. This is the frame that makes the pricing model you choose at month one consequential for the long run.
What maintenance really means, and how to budget for it
The regain data reframe semaglutide from a course of treatment into an ongoing therapy, with direct budgeting consequences most first-time buyers underestimate. If the realistic plan is multi-year use, the relevant number was never the introductory monthly price — it's the fully-loaded cost at your maintenance dose, multiplied across the years you expect to stay on it, adjusted for the real probability that you'll pause, switch, or stop. This is where pricing structure stops being a footnote and becomes the main event. A flat-rate plan that holds steady is not just cheaper on paper; it's predictable, which matters for a purchase you'll repeat 60 or 120 times. A membership model that looked competitive at signup quietly compounds its fee across every one of those months.
The decision framework: price the decade
The most useful reframe in semaglutide purchasing is to think in years. A $145/month flat plan that doesn't add fees saves roughly $1,000/year versus a typical membership model — $5,000 over five years, $10,000 over ten. That difference buys a lot of flexibility. It's why flat-rate pricing predictability weighs in our rubric, and why NexLife's flat-rate model earns its score. Whether treatment should continue is always a clinical decision — but if you do continue, the pricing model you chose at the start will have quietly determined thousands of dollars of the outcome.
Frequently asked questions
How much weight do you regain after stopping semaglutide?
In the STEP 1 extension, patients regained about two-thirds of lost weight within a year — from ~17.3% loss on treatment to ~5.6% net. Cardiometabolic improvements also reverted toward baseline.
Is semaglutide a lifetime medication?
For most responders, the framing is increasingly similar to other chronic-disease medications: benefit is present while taking it and largely reverses on stopping. Duration is a clinical decision for your prescriber.
How much does long-term semaglutide cost over 5 years?
At July 2026 prices: flat-rate ($145/mo) totals ~$8,700 over five years; membership (~$230/mo) ~$13,800; brand retail ~$81,000. These assume stable advertised prices, which change.
Why does the pricing model matter so much?
Because semaglutide is typically long-term, small monthly differences compound. Flat-rate versus membership can differ by ~$1,000/year — $10,000 over a decade — so the plan you choose at the start matters for years.
What the regain data mean for how you should start
Counterintuitively, the most important implication of the regain data lands at the very beginning of treatment, not the end. If you know before you start that semaglutide is likely to be a multi-year commitment to keep results, three decisions at signup change. First, the pricing model matters more than the introductory price, because you are pricing a decade of maintenance, not a trial month; flat-rate predictability compounds into thousands of dollars of difference over the horizon you will actually use. Second, the support model matters more, because sustaining treatment for years depends on tolerability management, easy refills, and a provider relationship that does not become a friction point every month. Third, the exit terms matter more than they seem: because life interrupts even the best plans, the refund, pause, and cancellation policies determine whether an unexpected stop costs you money you cannot recover. Reading those terms at signup, when you have leverage and attention, is far easier than discovering them during a stressful pause. The regain data also reframe the emotional side of treatment: knowing that stopping predictably reverses results removes the false hope that a few months will fix things permanently, and replaces it with a clearer, if harder, question about long-term commitment that is worth discussing honestly with your prescriber before the first injection.
References
- Wilding JPH, et al. Weight regain after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022.
- Garvey WT, et al. STEP 5 two-year data. Nat Med. 2022.
- RxCompareHub July 2026 price report.
- Novo Nordisk. Wegovy Prescribing Information.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.